Last reviewed · How we verify

Spinal analgesia

McGill University Health Centre/Research Institute of the McGill University Health Centre · FDA-approved active Small molecule ✓ Verified May 2026

Spinal analgesia is a Small molecule drug developed by McGill University Health Centre/Research Institute of the McGill University Health Centre. It is currently FDA-approved for Acute postoperative pain, Chronic pain conditions, Cancer pain. Also known as: Spinal block, intrathecal block, Analgesia cocktail.

Spinal analgesia delivers pain-relieving medications directly into the cerebrospinal fluid around the spinal cord to block pain signals at their source.

Spinal analgesia is a form of regional anesthesia involving the injection of a local anesthetic into the subarachnoid space. It is typically administered through a fine needle as a single-shot dose, although continuous spinal anesthesia can also be achieved through an intrathecal catheter.

At a glance

Generic nameSpinal analgesia
Also known asSpinal block, intrathecal block, Analgesia cocktail
SponsorMcGill University Health Centre/Research Institute of the McGill University Health Centre
ModalitySmall molecule
Therapeutic areaPain Management
PhaseFDA-approved

Mechanism of action

This is an administration route and technique rather than a specific drug entity. Spinal analgesia involves injecting analgesic agents (such as local anesthetics, opioids, or other pain medications) into the intrathecal space surrounding the spinal cord. By delivering medications directly to the central nervous system at the spinal level, it achieves potent pain relief with lower systemic doses, reducing side effects compared to systemic administration.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Spinal analgesia

What is Spinal analgesia?

Spinal analgesia is a Small molecule drug developed by McGill University Health Centre/Research Institute of the McGill University Health Centre, indicated for Acute postoperative pain, Chronic pain conditions, Cancer pain.

How does Spinal analgesia work?

Spinal analgesia delivers pain-relieving medications directly into the cerebrospinal fluid around the spinal cord to block pain signals at their source.

What is Spinal analgesia used for?

Spinal analgesia is indicated for Acute postoperative pain, Chronic pain conditions, Cancer pain, Labor pain.

Who makes Spinal analgesia?

Spinal analgesia is developed and marketed by McGill University Health Centre/Research Institute of the McGill University Health Centre (see full McGill University Health Centre/Research Institute of the McGill University Health Centre pipeline at /company/mcgill-university-health-centre-research-institute-of-the-mcgill-university-heal).

Is Spinal analgesia also known as anything else?

Spinal analgesia is also known as Spinal block, intrathecal block, Analgesia cocktail.

What development phase is Spinal analgesia in?

Spinal analgesia is FDA-approved (marketed).

What are the side effects of Spinal analgesia?

Common side effects of Spinal analgesia include Headache (post-dural puncture), Hypotension, Urinary retention, Pruritus, Nausea.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing